Yoichi Takami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoichi Takami has a total of 261 co-authors. Here are the top co-authors by number of shared publications:
- Hiromi Rakugi
Department of Geriatric and General Medicine The University of Osaka Graduate School of Medicine Suita Japan
22 shared publications - Hironori Nakagami
Department of Health Development and Medicine Osaka University Graduate School of Medicine Osaka Japan
17 shared publications Hikari Takeshita
Department of Geriatric and General Medicine The University of Osaka Graduate School of Medicine Osaka Japan
15 shared publicationsKoichi Yamamoto
Department of Geriatric and General Medicine, Graduate School of Medicine The University of Osaka Osaka Japan
15 shared publicationsYasushi Takeya
Division of Health Sciences, Graduate School of Medicine The University of Osaka Osaka Japan
15 shared publications- Koichi Yamamoto
Department of Geriatric and General Medicine The University of Osaka Graduate School of Medicine Osaka Japan
14 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Aging Cell
- Vol. 25 (11)
Senescence‐Associated Loss of α‐Synuclein in Brain Microvascular Endothelium Compromises Tight Junctions and Disrupts Blood–Brain Barrier Integrity
Blood–brain barrier (BBB) dysfunction is an early feature of brain aging, but the endothelial mechanisms preserving barrier resilience remain unclear. Although we have reported α‐synuclein (SNCA) supports vascular endothelial homeostasis, its role in the brain microvascular endothelium is unknown. Because SNCA loss suppresses eNOS/NO signaling and promotes endothelial β‐site amyloid precursor protein cleaving enzyme 1 (BACE1) induction, we investigated whether senescence‐associated SNCA decline drives BACE1‐dependent BBB injury. Replicative senescence in human brain microvascular endothelial cells (HBMECs) reduced SNCA expression. siRNA‐mediated SNCA depletion induced a senescence‐like state with increased β‐galactosidase activity, CDKN2A/p16 and TP53/p53 induction, and decreased SIRT1, eNOS, and glypican‐1. SNCA‐deficient HBMECs showed impaired proliferation and migration, loss of occludin and ZO‐1, increased permeability, and elevated BACE1 expression and activity; BACE1 co‐silencing restored junctional proteins and normalized permeability. Transcriptomic and proteomic profiling excluded most classical BACE1‐regulatory mechanisms and instead implicated coordinated disruption of the NO–sGC–cGMP axis, consistent with the partial rescue by the NO donor SNAP. Amyloid‐β42 oligomers sensitized SNCA‐deficient monolayers to barrier injury at concentrations that left control monolayers unaffected. Global SNCA‐knockout mice exhibited multiregional BBB leakage, reduced occludin, ZO‐1, and claudin‐5, and p53 immunoreactivity confined to CD31‐positive microvessels. This phenotype was present in young adulthood and was reproduced in aged wild‐type mice, which showed reduced SNCA in isolated brain microvessels. These findings identify senescence‐associated endothelial SNCA loss as a candidate contributor to brain microvascular barrier vulnerability, describing an endothelial stress pathway in which SNCA insufficiency is associated with BACE1‐dependent tight junction destabilization in the aging brain.
- 9 November 2026
- Published by Wiley in Aging Cell
- Vol. 25 (11)
Open AccessSenescence‐Associated Loss of α‐Synuclein in Brain Microvascular Endothelium Compromises Tight Junctions and Disrupts Blood–Brain Barrier Integrity
Blood–brain barrier (BBB) dysfunction is an early feature of brain aging, but the endothelial mechanisms preserving barrier resilience remain unclear. Although we have reported α‐synuclein (SNCA) supports vascular endothelial homeostasis, its role in the brain microvascular endothelium is unknown. Because SNCA loss suppresses eNOS/NO signaling and promotes endothelial β‐site amyloid precursor protein cleaving enzyme 1 (BACE1) induction, we investigated whether senescence‐associated SNCA decline drives BACE1‐dependent BBB injury. Replicative senescence in human brain microvascular endothelial cells (HBMECs) reduced SNCA expression. siRNA‐mediated SNCA depletion induced a senescence‐like state with increased β‐galactosidase activity, CDKN2A/p16 and TP53/p53 induction, and decreased SIRT1, eNOS, and glypican‐1. SNCA‐deficient HBMECs showed impaired proliferation and migration, loss of occludin and ZO‐1, increased permeability, and elevated BACE1 expression and activity; BACE1 co‐silencing restored junctional proteins and normalized permeability. Transcriptomic and proteomic profiling excluded most classical BACE1‐regulatory mechanisms and instead implicated coordinated disruption of the NO–sGC–cGMP axis, consistent with the partial rescue by the NO donor SNAP. Amyloid‐β42 oligomers sensitized SNCA‐deficient monolayers to barrier injury at concentrations that left control monolayers unaffected. Global SNCA‐knockout mice exhibited multiregional BBB leakage, reduced occludin, ZO‐1, and claudin‐5, and p53 immunoreactivity confined to CD31‐positive microvessels. This phenotype was present in young adulthood and was reproduced in aged wild‐type mice, which showed reduced SNCA in isolated brain microvessels. These findings identify senescence‐associated endothelial SNCA loss as a candidate contributor to brain microvascular barrier vulnerability, describing an endothelial stress pathway in which SNCA insufficiency is associated with BACE1‐dependent tight junction destabilization in the aging brain.
- Open Access
- 14 October 2026
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 26 (10)
Comparison of Metabolic Dysfunction‐Associated Steatotic Liver Disease Between Individuals With Werner Syndrome and Those With Insulin‐Resistant Type 2 Diabetes: Hepatic Steatosis and Fibrosis Indices
Aim: This study compared metabolic dysfunction‐associated steatotic liver disease (MASLD) in individuals with Werner syndrome (WS) and individuals with insulin‐resistant type 2 diabetes (T2D). It also examined the association with imaging findings of MASLD in individuals with WS, clarified the characteristics of MASLD that accompany WS, and identified useful indices for its diagnosis in addition to imaging. Methods: Three hepatic steatosis and two hepatic fibrosis indices in 48 individuals enrolled in the Japanese Werner Syndrome Registry were compared with those in 101 Japanese individuals with insulin‐resistant T2D from another clinical study. In individuals with WS, the liver/spleen ratio (L/S ratio) was calculated from computed tomography (CT) images, and its associations with each index were examined. Statistical analyses were performed using the Welch test and pairwise comparisons. Results: Individuals with WS had lower hepatic steatosis and fibrosis index values than those with insulin‐resistant T2D. The mean L/S ratio calculated from CT images was 1.05 ± 0.24 in individuals with WS. The L/S ratio, which is one of the indicators for diagnosing MASLD, was < 0.9 in 5 of 20 cases (25%). Among the various indices in individuals with WS, only the hepatic steatosis index (HSI) was correlated with the L/S ratio ( r = −0.863, p = 0.0003). Conclusions: The prevalence of MASLD is lower in individuals with WS than in those with insulin‐resistant T2D. The HSI was associated with the L/S ratio in individuals with WS, suggesting that HSI may reflect hepatic steatosis‐related changes in this population. Further studies in larger cohorts are needed to validate these findings. Trial Registration: The study was registered at the UMIN Clinical Trial Registry ( https://upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000034058 ) on November 3, 2017 (ID: UMIN000029812)
- 14 October 2026
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 26 (10)
Open AccessComparison of Metabolic Dysfunction‐Associated Steatotic Liver Disease Between Individuals With Werner Syndrome and Those With Insulin‐Resistant Type 2 Diabetes: Hepatic Steatosis and Fibrosis Indices
Aim: This study compared metabolic dysfunction‐associated steatotic liver disease (MASLD) in individuals with Werner syndrome (WS) and individuals with insulin‐resistant type 2 diabetes (T2D). It also examined the association with imaging findings of MASLD in individuals with WS, clarified the characteristics of MASLD that accompany WS, and identified useful indices for its diagnosis in addition to imaging. Methods: Three hepatic steatosis and two hepatic fibrosis indices in 48 individuals enrolled in the Japanese Werner Syndrome Registry were compared with those in 101 Japanese individuals with insulin‐resistant T2D from another clinical study. In individuals with WS, the liver/spleen ratio (L/S ratio) was calculated from computed tomography (CT) images, and its associations with each index were examined. Statistical analyses were performed using the Welch test and pairwise comparisons. Results: Individuals with WS had lower hepatic steatosis and fibrosis index values than those with insulin‐resistant T2D. The mean L/S ratio calculated from CT images was 1.05 ± 0.24 in individuals with WS. The L/S ratio, which is one of the indicators for diagnosing MASLD, was < 0.9 in 5 of 20 cases (25%). Among the various indices in individuals with WS, only the hepatic steatosis index (HSI) was correlated with the L/S ratio ( r = −0.863, p = 0.0003). Conclusions: The prevalence of MASLD is lower in individuals with WS than in those with insulin‐resistant T2D. The HSI was associated with the L/S ratio in individuals with WS, suggesting that HSI may reflect hepatic steatosis‐related changes in this population. Further studies in larger cohorts are needed to validate these findings. Trial Registration: The study was registered at the UMIN Clinical Trial Registry ( https://upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000034058 ) on November 3, 2017 (ID: UMIN000029812)
- Open Access
- 2 August 2026
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 26 (8)
Characterization of Usage Patterns of Drugs Suspected to Cause Adverse Drug Reactions in Older Hospitalized Patients
Aim: This study aimed to characterize the usage patterns of drugs suspected to cause adverse drug reactions (ADRs) in older hospitalized patients. Methods: Medical records of older adults admitted to the Department of Geriatrics and Hypertension at Osaka University Hospital from September 2014 to August 2021 were reviewed. The probability of ADRs was retrospectively assessed using the Naranjo ADR Probability Scale. Patients were categorized into two groups according to whether the suspected drugs were prescribed before admission (continuous‐use group) or were newly initiated or modified after admission (new/changed‐use group). The types and frequency of ADRs, timing of ADR onset, and suspected drugs identified were summarized according to the usage patterns. Results: ADRs were identified in 5.6% ( n = 79) of eligible hospitalizations ( N = 1418). In the continuous‐use group ( n = 39), antihypertensives were the most frequently identified suspected drugs (46.2%), followed by diuretics (17.9%), analgesics (12.8%), and antidiabetic drugs (7.7%); the most common ADRs were hypotension (35.9%), bradycardia/tachycardia (17.9%), and electrolyte abnormalities (17.9%). In the new/changed‐use group, antihypertensives were also the most frequently identified suspected drugs (15.0%), followed by antibiotics, diuretics, antidementia drugs, and analgesics (10.0%); the ADRs included hypotension (22.5%), nausea and vomiting (17.5%), and electrolyte abnormalities (15.0%). Most ADRs occurred within the first week of hospitalization, except for electrolyte abnormalities, which often appeared during the first 2 weeks of hospitalization. Conclusions: This study identified ADRs and suspected drugs according to the usage patterns in older hospitalized patients. Close monitoring of both newly prescribed and continuously used drugs is crucial, particularly during the first weeks of hospitalization.
- 2 August 2026
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 26 (8)
Open AccessCharacterization of Usage Patterns of Drugs Suspected to Cause Adverse Drug Reactions in Older Hospitalized Patients
Aim: This study aimed to characterize the usage patterns of drugs suspected to cause adverse drug reactions (ADRs) in older hospitalized patients. Methods: Medical records of older adults admitted to the Department of Geriatrics and Hypertension at Osaka University Hospital from September 2014 to August 2021 were reviewed. The probability of ADRs was retrospectively assessed using the Naranjo ADR Probability Scale. Patients were categorized into two groups according to whether the suspected drugs were prescribed before admission (continuous‐use group) or were newly initiated or modified after admission (new/changed‐use group). The types and frequency of ADRs, timing of ADR onset, and suspected drugs identified were summarized according to the usage patterns. Results: ADRs were identified in 5.6% ( n = 79) of eligible hospitalizations ( N = 1418). In the continuous‐use group ( n = 39), antihypertensives were the most frequently identified suspected drugs (46.2%), followed by diuretics (17.9%), analgesics (12.8%), and antidiabetic drugs (7.7%); the most common ADRs were hypotension (35.9%), bradycardia/tachycardia (17.9%), and electrolyte abnormalities (17.9%). In the new/changed‐use group, antihypertensives were also the most frequently identified suspected drugs (15.0%), followed by antibiotics, diuretics, antidementia drugs, and analgesics (10.0%); the ADRs included hypotension (22.5%), nausea and vomiting (17.5%), and electrolyte abnormalities (15.0%). Most ADRs occurred within the first week of hospitalization, except for electrolyte abnormalities, which often appeared during the first 2 weeks of hospitalization. Conclusions: This study identified ADRs and suspected drugs according to the usage patterns in older hospitalized patients. Close monitoring of both newly prescribed and continuously used drugs is crucial, particularly during the first weeks of hospitalization.
- Open Access
- 30 June 2026
- Published by Elsevier in STAR Protocols
- Vol. 7 (3) , 104664
Protocol for quantitative live-cell imaging of early GPCR trafficking using acid-stable afCFP-Venus FRET
- 30 June 2026
- Published by Elsevier in STAR Protocols
- Vol. 7 (3) , 104664
Open AccessProtocol for quantitative live-cell imaging of early GPCR trafficking using acid-stable afCFP-Venus FRET
- 20 August 2025
- Published by Springer Nature in Hypertension Research
- Vol. 48 (11) , 3057-3058
Short-duration part-time light work and real-time blood pressure variability in older adults: a pilot observational study using cuffless technology at Expo 2025 Osaka
- 20 August 2025
- Published by Springer Nature in Hypertension Research
- Vol. 48 (11) , 3057-3058
Short-duration part-time light work and real-time blood pressure variability in older adults: a pilot observational study using cuffless technology at Expo 2025 Osaka
- Open Access
- 12 August 2025
- Published by Springer Nature in Hypertension Research
- Vol. 48 (10) , 2527-2536
Targeting a systolic blood pressure of <130 mmHg is beneficial in adults with hypertension aged ≥75 years: a systematic review and meta-analysis
Recent clinical trials have raised important questions regarding optimal blood pressure (BP) targets in older adults with hypertension. In the 2019 Japanese Society of Hypertension guidelines, a systolic BP (SBP) target of p = 0.03), all-cause mortality (RR: 0.72, 95% CI: 0.56–0.93, p = 0.01), and cardiovascular mortality (RR: 0.55, 95% CI: 0.35–0.88, p = 0.01), with no increase in serious adverse events (RR: 1.00, 95% CI: 0.93–1.08, p = 0.97). Stroke incidence did not differ significantly between groups. Similar results were observed when the analysis was expanded to include studies that enrolled participants aged ≥70 years. These findings support the safety and clinical benefits of targeting an SBP of <130 mmHg in older adults with hypertension.
- 12 August 2025
- Published by Springer Nature in Hypertension Research
- Vol. 48 (10) , 2527-2536
Open AccessTargeting a systolic blood pressure of <130 mmHg is beneficial in adults with hypertension aged ≥75 years: a systematic review and meta-analysis
Recent clinical trials have raised important questions regarding optimal blood pressure (BP) targets in older adults with hypertension. In the 2019 Japanese Society of Hypertension guidelines, a systolic BP (SBP) target of p = 0.03), all-cause mortality (RR: 0.72, 95% CI: 0.56–0.93, p = 0.01), and cardiovascular mortality (RR: 0.55, 95% CI: 0.35–0.88, p = 0.01), with no increase in serious adverse events (RR: 1.00, 95% CI: 0.93–1.08, p = 0.97). Stroke incidence did not differ significantly between groups. Similar results were observed when the analysis was expanded to include studies that enrolled participants aged ≥70 years. These findings support the safety and clinical benefits of targeting an SBP of <130 mmHg in older adults with hypertension.
- Open Access
- 18 June 2025
- Published by Springer Nature in Hypertension Research
- Vol. 48 (9) , 2376-2386
Oxidized LDL enhances Gq signaling and aldosterone production by angiotensin II via the AT1-LOX-1 receptor complex in adrenal cells
We previously reported that oxidized low-density lipoprotein (oxLDL) activates the angiotensin II (AII) type 1 receptor (AT1) through the lectin-like oxLDL receptor (LOX-1)-AT1 complex. While oxLDL alone does not activate G protein αq (Gq), its simultaneous binding with AII alters AT1 structure, enhancing Gq activation. We investigated this interaction’s effect on aldosterone production in adrenal glands. Human adrenal cells (H295R) were treated with vehicle, oxLDL, AII, or a combination of oxLDL and AII. Gq signaling was assessed using inositol monophosphate (IP1) assays, Ca influx using Fura2, and aldosterone synthesis gene expression using qRT-PCR. Wild-type (WT) and LOX-1 knockout (KO) mice were fed a normal diet (ND) or high-fat diet (HFD) in vivo to elevate oxLDL levels, followed by subcutaneous AII or saline infusion for 4 weeks (long-term) or 3 days (short-term). In H295R cells, oxLDL alone did not induce IP1 production; however, AII-induced IP1 and Ca influx were enhanced by oxLDL. These effects were abolished by LOX-1 siRNA. Co-administration of oxLDL and AII upregulated aldosterone synthesis genes, such as CYP11B2; this effect was suppressed by a Gq inhibitor. In vivo, long-term AII and HFD administration increased adrenal CYP11B2 expression but not serum aldosterone levels. Conversely, short-term AII and oxLDL administration elevated serum aldosterone levels, but not CYP11B2 expression. These effects were absent in LOX-1 KO mice. Blood pressure was unaffected by HFD or oxLDL in both models. In conclusion, OxLDL enhances AII-induced aldosterone production in adrenal glands through LOX-1-AT1 interaction, although its impact on blood pressure regulation remains unclear.
- 18 June 2025
- Published by Springer Nature in Hypertension Research
- Vol. 48 (9) , 2376-2386
Open AccessOxidized LDL enhances Gq signaling and aldosterone production by angiotensin II via the AT1-LOX-1 receptor complex in adrenal cells
We previously reported that oxidized low-density lipoprotein (oxLDL) activates the angiotensin II (AII) type 1 receptor (AT1) through the lectin-like oxLDL receptor (LOX-1)-AT1 complex. While oxLDL alone does not activate G protein αq (Gq), its simultaneous binding with AII alters AT1 structure, enhancing Gq activation. We investigated this interaction’s effect on aldosterone production in adrenal glands. Human adrenal cells (H295R) were treated with vehicle, oxLDL, AII, or a combination of oxLDL and AII. Gq signaling was assessed using inositol monophosphate (IP1) assays, Ca influx using Fura2, and aldosterone synthesis gene expression using qRT-PCR. Wild-type (WT) and LOX-1 knockout (KO) mice were fed a normal diet (ND) or high-fat diet (HFD) in vivo to elevate oxLDL levels, followed by subcutaneous AII or saline infusion for 4 weeks (long-term) or 3 days (short-term). In H295R cells, oxLDL alone did not induce IP1 production; however, AII-induced IP1 and Ca influx were enhanced by oxLDL. These effects were abolished by LOX-1 siRNA. Co-administration of oxLDL and AII upregulated aldosterone synthesis genes, such as CYP11B2; this effect was suppressed by a Gq inhibitor. In vivo, long-term AII and HFD administration increased adrenal CYP11B2 expression but not serum aldosterone levels. Conversely, short-term AII and oxLDL administration elevated serum aldosterone levels, but not CYP11B2 expression. These effects were absent in LOX-1 KO mice. Blood pressure was unaffected by HFD or oxLDL in both models. In conclusion, OxLDL enhances AII-induced aldosterone production in adrenal glands through LOX-1-AT1 interaction, although its impact on blood pressure regulation remains unclear.
- Open Access
- 25 March 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Oxidized low-density lipoprotein potentiates angiotensin II-induced Gq activation through the AT1-LOX1 receptor complex
Chronic kidney disease (CKD) and atherosclerotic heart disease, frequently associated with dyslipidemia and hypertension, represent significant health concerns. We investigated the interplay among these conditions, focusing on the role of oxidized low-density lipoprotein (oxLDL) and angiotensin II (Ang II) in renal injury via G protein αq subunit (Gq) signaling. We hypothesized that oxLDL enhances Ang II-induced Gq signaling via the AT1 (Ang II type 1 receptor)-LOX1 (lectin-like oxLDL receptor) complex. Based on CHO and renal cell model experiments, oxLDL alone did not activate Gq signaling. However, when combined with Ang II, it significantly potentiated Gq-mediated inositol phosphate 1 production and calcium influx in cells expressing both LOX-1 and AT1 but not in AT1-expressing cells. This suggests a critical synergistic interaction between oxLDL and Ang II in the AT1-LOX1 complex. Conformational studies using AT1 biosensors have indicated a unique receptor conformational change due to the oxLDL-Ang II combination. In vivo, wild-type mice fed a high-fat diet with Ang II infusion presented exacerbated renal dysfunction, whereas LOX-1 knockout mice did not, underscoring the pathophysiological relevance of the AT1-LOX1 interaction in renal damage. These findings highlight a novel mechanism of renal dysfunction in CKD driven by dyslipidemia and hypertension and suggest the therapeutic potential of AT1-LOX1 receptor complex in patients with these comorbidities.
- 25 March 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessOxidized low-density lipoprotein potentiates angiotensin II-induced Gq activation through the AT1-LOX1 receptor complex
Chronic kidney disease (CKD) and atherosclerotic heart disease, frequently associated with dyslipidemia and hypertension, represent significant health concerns. We investigated the interplay among these conditions, focusing on the role of oxidized low-density lipoprotein (oxLDL) and angiotensin II (Ang II) in renal injury via G protein αq subunit (Gq) signaling. We hypothesized that oxLDL enhances Ang II-induced Gq signaling via the AT1 (Ang II type 1 receptor)-LOX1 (lectin-like oxLDL receptor) complex. Based on CHO and renal cell model experiments, oxLDL alone did not activate Gq signaling. However, when combined with Ang II, it significantly potentiated Gq-mediated inositol phosphate 1 production and calcium influx in cells expressing both LOX-1 and AT1 but not in AT1-expressing cells. This suggests a critical synergistic interaction between oxLDL and Ang II in the AT1-LOX1 complex. Conformational studies using AT1 biosensors have indicated a unique receptor conformational change due to the oxLDL-Ang II combination. In vivo, wild-type mice fed a high-fat diet with Ang II infusion presented exacerbated renal dysfunction, whereas LOX-1 knockout mice did not, underscoring the pathophysiological relevance of the AT1-LOX1 interaction in renal damage. These findings highlight a novel mechanism of renal dysfunction in CKD driven by dyslipidemia and hypertension and suggest the therapeutic potential of AT1-LOX1 receptor complex in patients with these comorbidities.
- Open Access
- 17 January 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Oxidized low-density lipoprotein potentiates angiotensin II-induced Gq activation through the AT1-LOX1 receptor complex: Implications for renal dysfunction
Chronic kidney disease (CKD) and atherosclerotic heart disease, frequently associated with dyslipidemia and hypertension, represent significant health concerns. We investigated the interplay among these conditions, focusing on the role of oxidized low-density lipoprotein (oxLDL) and angiotensin II (Ang II) in renal injury via G protein αq subunit (Gq) signaling. We hypothesized that oxLDL enhances Ang II-induced Gq signaling via the AT1 (Ang II type 1 receptor)-LOX1 (lectin-like oxLDL receptor) complex. Based on CHO and renal cell model experiments, oxLDL alone did not activate Gq signaling. However, when combined with Ang II, it significantly potentiated Gq-mediated inositol phosphate 1 production and calcium influx in cells expressing both LOX-1 and AT1 but not in AT1-expressing cells. This suggests a critical synergistic interaction between oxLDL and Ang II in the AT1-LOX1 complex. Conformational studies using AT1 biosensors have indicated a unique receptor conformational change due to the oxLDL-Ang II combination. In vivo, wild-type mice fed a high-fat diet with Ang II infusion presented exacerbated renal dysfunction, whereas LOX-1 knockout mice did not, underscoring the pathophysiological relevance of the AT1-LOX1 interaction in renal damage. These findings highlight a novel mechanism of renal dysfunction in CKD driven by dyslipidemia and hypertension and suggest the therapeutic potential of AT1-LOX1 receptor complex in patients with these comorbidities.
- 17 January 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Open AccessOxidized low-density lipoprotein potentiates angiotensin II-induced Gq activation through the AT1-LOX1 receptor complex: Implications for renal dysfunction
Chronic kidney disease (CKD) and atherosclerotic heart disease, frequently associated with dyslipidemia and hypertension, represent significant health concerns. We investigated the interplay among these conditions, focusing on the role of oxidized low-density lipoprotein (oxLDL) and angiotensin II (Ang II) in renal injury via G protein αq subunit (Gq) signaling. We hypothesized that oxLDL enhances Ang II-induced Gq signaling via the AT1 (Ang II type 1 receptor)-LOX1 (lectin-like oxLDL receptor) complex. Based on CHO and renal cell model experiments, oxLDL alone did not activate Gq signaling. However, when combined with Ang II, it significantly potentiated Gq-mediated inositol phosphate 1 production and calcium influx in cells expressing both LOX-1 and AT1 but not in AT1-expressing cells. This suggests a critical synergistic interaction between oxLDL and Ang II in the AT1-LOX1 complex. Conformational studies using AT1 biosensors have indicated a unique receptor conformational change due to the oxLDL-Ang II combination. In vivo, wild-type mice fed a high-fat diet with Ang II infusion presented exacerbated renal dysfunction, whereas LOX-1 knockout mice did not, underscoring the pathophysiological relevance of the AT1-LOX1 interaction in renal damage. These findings highlight a novel mechanism of renal dysfunction in CKD driven by dyslipidemia and hypertension and suggest the therapeutic potential of AT1-LOX1 receptor complex in patients with these comorbidities.
- Open Access
- 4 December 2024
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 27 (1)
Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)
Sacubitril/valsartan, an angiotensin receptor‐neprilysin inhibitor, has demonstrated a superior blood pressure‐lowering effect compared with renin‐angiotensin system inhibitors in several clinical trials. However, there has been no available evidence on the comparison between sacubitril/valsartan and calcium channel blockers (CCBs), a well‐established class of antihypertensive drugs.In this open‐label, multicenter study, we aimed to demonstrate the efficacy and safety of sacubitril/valsartan versus amlodipine, one of the most widely used CCBs, after 8 weeks of treatment. A total of 359 Japanese patients with essential hypertension (office systolic blood pressure [SBP] ≥ 150 to < 180 mmHg), aged 18–79, were randomly assigned to receive either once‐daily sacubitril/valsartan 200 mg or once‐daily amlodipine 5 mg in a 1:1 allocation ratio. The primary endpoint was the noninferiority of sacubitril/valsartan compared with amlodipine in mean change in 24‐h SBP from baseline to Week 8, followed by a significance test as a secondary endpoint analysis. The mean change in 24‐h SBP in sacubitril/valsartan was noninferior to that in amlodipine (between‐treatment difference −0.62 mmHg [95% confidential interval: −3.23 to 1.98; p = 0.003 for noninferiority; independent t‐test with noninferiority margin 3.0 mmHg]), with no significant difference observed (p = 0.637). There was no significant difference in the incidence of adverse events (AEs). These results suggested that the blood pressure‐lowering effect of sacubitril/valsartan is comparable to that of amlodipine, with no marked differences in tolerability between the two groups. Sacubitril/valsartan, a potent antihypertensive drug comparable to amlodipine, is expected to improve blood pressure control in clinical practice.
- 4 December 2024
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 27 (1)
Open AccessEfficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)
Sacubitril/valsartan, an angiotensin receptor‐neprilysin inhibitor, has demonstrated a superior blood pressure‐lowering effect compared with renin‐angiotensin system inhibitors in several clinical trials. However, there has been no available evidence on the comparison between sacubitril/valsartan and calcium channel blockers (CCBs), a well‐established class of antihypertensive drugs.In this open‐label, multicenter study, we aimed to demonstrate the efficacy and safety of sacubitril/valsartan versus amlodipine, one of the most widely used CCBs, after 8 weeks of treatment. A total of 359 Japanese patients with essential hypertension (office systolic blood pressure [SBP] ≥ 150 to < 180 mmHg), aged 18–79, were randomly assigned to receive either once‐daily sacubitril/valsartan 200 mg or once‐daily amlodipine 5 mg in a 1:1 allocation ratio. The primary endpoint was the noninferiority of sacubitril/valsartan compared with amlodipine in mean change in 24‐h SBP from baseline to Week 8, followed by a significance test as a secondary endpoint analysis. The mean change in 24‐h SBP in sacubitril/valsartan was noninferior to that in amlodipine (between‐treatment difference −0.62 mmHg [95% confidential interval: −3.23 to 1.98; p = 0.003 for noninferiority; independent t‐test with noninferiority margin 3.0 mmHg]), with no significant difference observed (p = 0.637). There was no significant difference in the incidence of adverse events (AEs). These results suggested that the blood pressure‐lowering effect of sacubitril/valsartan is comparable to that of amlodipine, with no marked differences in tolerability between the two groups. Sacubitril/valsartan, a potent antihypertensive drug comparable to amlodipine, is expected to improve blood pressure control in clinical practice.